SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune Inc is trending following positive topline Phase 2b data for its MASH drug, pemvidutide, which demonstrated statistically significant improvements in key non-invasive liver tests and a favorable tolerability profile, with the FDA supporting a registrational Phase 3 trial. The community is actively discussing whether the initial market reaction is a "sell the news" event or a strategic accumulation by institutions, amid ongoing speculation about potential partnerships or a buyout to fund the next stage of development for this promising asset.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending lower following its recent financial results, which highlighted weak demand in the crucial China market and concerns over gross margin compression. Community discussion centers on whether the brand is losing appeal to younger consumers amidst rising competition and questions around management's strategy, with some viewing the dip as a buying opportunity while others express long-term skepticism.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is trending amid an escalating legal battle, with the company filing a lawsuit alleging stock manipulation by certain investment funds. This high-stakes action has fueled intense community debate, as investors grapple with GRRR's continued stock decline despite recent positive business developments, including substantial contracts and an expanded share buyback program. Many believe the stock is deeply undervalued and is being suppressed by targeted short activity and external pressures unrelated to its core AI and infrastructure business.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines (LUNR) is capturing market attention following bullish analyst upgrades and the confirmation of Jared Isaacman as NASA Administrator, aligning with a new White House executive order for American space superiority. The community is highly anticipating the imminent, multi-billion-dollar Lunar Terrain Vehicle (LTV) contract award, believing LUNR is a leading contender due to its proven lunar mission success. This confluence of catalysts, coupled with heavy short interest, suggests continued volatility and strong upside potential.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is experiencing a surge in conversation following multiple analyst upgrades, with price targets raised to $25, coupled with the significant expansion of its "Universal Hands-Free" assisted driving feature across millions of miles of roads. The community is actively discussing Rivian's transition from a pure EV manufacturer to a leader in autonomy and software, driven by its in-house AI chip development and upcoming R2 launch, igniting hopes for a major short squeeze.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata Inc. is heavily trending due to high anticipation for a strategic partnership announcement, expected before year-end, which CEO Jack Abuhoff has called a "game-changer" for its AI solutions in the government and military sectors. The community is sharply divided, with bulls foreseeing a significant rally from current oversold levels and speculating a major partner like Palantir or Lockheed Martin, while others express frustration over past unfulfilled predictions and the stock's price action amidst broader small-cap and AI market bearishness.

FedEx Corp. is a holding company, which engages in the provision of transportation, e-commerce, business services, and business solutions. It operates through the following segments: FedEx Express, FedEx Freight, Corporate, Other, and Eliminations. The FedEx Express segment offers transportation and delivery services. The FedEx Freight segment refers to freight transportation services to business and residences. The FedEx Services segment includes sales, marketing, information technology, communications, customer service, technical support, billing and collection services, and certain back-office functions that support the company's operating segments. The Corporate, Other, and Eliminations segment is involved in the corporate headquarters costs for executive officers and certain legal and finance functions, as well as certain other costs and credits not attributed to the firm's core business. The company was founded by Frederick Wallace Smith on June 18, 1971, and is headquartered in Memphis, TN.

Fedex Corp

FedEx is trending following stronger-than-expected financial results, driven by ongoing cost-cutting and network transformation initiatives. The community is actively debating the significance of the earnings beat and raised outlook, with bulls anticipating further upside, while others express caution regarding potential impacts from expiring trade exemptions and fierce industry competition. The immediate market reaction has been a key talking point, with some noting limited sustained gains despite the positive report.

WhiteFiber, Inc. provides AI and HPC infrastructure & cloud and data center solutions. It operates through the following segments: Cloud Services and Colocation Services. The Cloud Services segment offers computing services to support generative AI workstreams. The Colocation Services segment provides customers with physical space, power and cooling within the data center facility. The company was founded on August 15, 2024 and is headquartered in New York, NY.

Whitefiber Inc.

WhiteFiber, Inc.

WhiteFiber (WYFI) is trending due to a significant 10-year, $865 million colocation agreement with Nscale for AI infrastructure at its NC-1 data center, marking a major catalyst for the company. The community is buzzing with excitement over this long-term AI revenue visibility and the stock's notably low free float. This deal firmly positions WhiteFiber within the booming AI data center sector, drawing increased attention to its growth potential.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is actively trending following a landmark executive order to reclassify marijuana to Schedule III, a historic move recognizing its medical value and prompting Tilray's launch of Tilray Medical USA to expand its U.S. operations. Community discussions are vibrant, with many anticipating significant financial benefits like tax relief and broader market access, despite some short-term price volatility attributed to a "sell the news" reaction.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals ($MDGL) is trending due to recent EU approval of Rezdiffra, the first approved MASH therapy in Europe, sparking buyout speculation. Community discussions revolve around potential acquisition by larger pharmaceutical companies and the drug's market potential. Bullish sentiment is fueled by strong sales projections and the company's lead in the MASH treatment space, though some express concerns about competition and valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Up 6.3% - Time to Buy?

ARS Pharmaceuticals (NASDAQ:SPRY) Trading 6.3% Higher - What's Next...

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Rating of "Moderate Buy" from Analysts

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eight ratings firms that are presently covering the stock...

ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 8.1% - Here's What Happened

ARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Up 8.1% - What's Next...

Franklin Resources Inc. Sells 28,789 Shares of ARS Pharmaceuticals, Inc. $SPRY

Franklin Resources Inc. trimmed its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 1.5% during the second quarter, according to the company in its most recent disclosure...

ARS Pharmaceuticals (NASDAQ:SPRY) Raised to Hold at Zacks Research

Zacks Research upgraded shares of ARS Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Thursday...

ARS Pharmaceuticals (NASDAQ:SPRY) Trading Up 12.6% - Here's What Happened

ARS Pharmaceuticals (NASDAQ:SPRY) Trading Up 12.6% - Still a Buy...

ARS Pharmaceuticals (NASDAQ:SPRY) Sets New 1-Year Low After Insider Selling

ARS Pharmaceuticals (NASDAQ:SPRY) Hits New 1-Year Low After Insider Selling...

ARS Pharmaceuticals (NASDAQ:SPRY) COO Brian Dorsey Sells 21,828 Shares

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) COO Brian Dorsey sold 21,828 shares of the business's stock in a transaction that occurred on Thursday, November 13th. The shares were sold...

Insider Selling: ARS Pharmaceuticals (NASDAQ:SPRY) Insider Sells 166,380 Shares of Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) insider Justin Chakma sold 166,380 shares of ARS Pharmaceuticals stock in a transaction dated Wednesday, November 12th. The shares were sold...

ARS Pharmaceuticals (NASDAQ:SPRY) Insider Justin Chakma Sells 166,380 Shares

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) insider Justin Chakma sold 166,380 shares of the company's stock in a transaction on Wednesday, November 12th. The stock was sold at an...

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

ARS Pharmaceuticals Inc

Up more than 2%

Up 0–2%

Flat to down 2%

Down more than 2%

The S&P 500 is modestly lower so far in December, putting the Santa Claus rally in question. The Santa Claus rally refers to the market’s tendency to rise in the final weeks of the year—what do you expect from December 16 through December 31?

What do you expect the S&amp;P 500’s total return to be in the second half of December?

Stocktwits

What do you expect the S&P 500’s total return to be in the second half of December?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.43	--	--	N/A
Q3 '25	-$0.45	-$0.52	-14.59%	MISSED
Q2 '25	-$0.46	-$0.46	-0.43%	MISSED
Q1 '25	-$0.34	-$0.35	-3.45%	MISSED
Q4 '24	-$0.24	$0.48	302.11%	BEAT

SPRY
ARS Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest SPRY News

SPRYARS Pharmaceuticals Inc